The 2nd Annual Epigenetics Discovery Congress will take place September 8-9, 2016 in London. The conference will explore the potential of epigenetics in novel and existing therapeutics. It will focus on emerging trends in drug discovery, including evolving targets, inhibitors, biomarkers and clinical success across diseases. Over two days, speakers will discuss topics such as epigenetic regulation, environmental impacts, translational challenges, clinical biomarkers, cancer, neurodevelopment, and new inhibitor scaffolds. The goal is to provide a platform for researchers and industry to network, showcase discoveries, and discuss advances in the application of epigenetics to drug development.
2nd Epigenetics Discovery congress - Latest agendaTony Couch
Advancements in Epigenetics have certainly given us huge breakthroughs in drug discovery, development and effective diagnosis of diseases. Scientists are working towards making new developments and address challenges in epigenetics for cancer, neurodegenerative diseases and other ailments. The Epigenetics Discovery Congress will provide a platform to such scientists to present their work, learn what their peers are doing, share experiences and overcome challenges that the industry is facing.....
2nd Epigenetics Discovery congress - Latest agendaTony Couch
Advancements in Epigenetics have certainly given us huge breakthroughs in drug discovery, development and effective diagnosis of diseases. Scientists are working towards making new developments and address challenges in epigenetics for cancer, neurodegenerative diseases and other ailments. The Epigenetics Discovery Congress will provide a platform to such scientists to present their work, learn what their peers are doing, share experiences and overcome challenges that the industry is facing.....
Sonogenetic Locale Specific Activation of Universal Vectors for Xenobiotics -...Nejc Draganjec
The final goal of the project is to develop “BioBrick” for liposome produced by means of synthetic biology, that
has a construct for disintegration embedded in its membrane. Xenobiotic packaged in a liposome is not part
of pharmacodynamics since it is biologically unavailable. Which makes liposomes interesting candidates for
universal drug delivery vectors. In our case, liposome disintegration is initiated by non-invasive sonic signal
and carried out by a construct of a sensor and an active part embedded in a membrane. Sensor part of a
construct is mechanoreceptor/mechanotransducer which activates protein representing the active part of a
construct. After activation, active part carries out the dissolution of a compartmentalization function by means
of total disintegration of vector or only membrane perforation. After an opening of a vector, previously packed
xenobiotic becomes locally available with a high concentration in locale and thus high effect and low systemic
concentration and thus smaller chance of side effect. This approach is very specific for both, time and space
factors and at the same time has a very broad area of potential biomedical applications. Vector would be, in
a hypothetical scenario of practical use in oncology, first packed with chemotherapeutics/biological drugs,
administered intravenously and then medical staff would have an option of drug activation in specific locations.
Activation is very precise and at the same time offers an option of easy switching among many different
targets, for example between dominant tumor to many potential metastasis. Since location of activation is
not tied to biomarker, but rather takes advantage of other rapidly developing medical technologies, vector
remains universally and directly applicable for any patient and for a broad spectrum of pathologies in fields of
oncology (chemotherapeutics/biological drugs and other payloads, like local immune response enhancers),
autoimmune diseases (local immune suppressors, diabetes), parasitology (malaria drugs and plasmodium
sporozoite), local pathologies (ulcer, trauma healing) . . .
Regular cancer treatment focuses on killing the cancer cells through large doses of medicine, but it also kills other cells in the body and causes significant side effects and potential long-term effects. UCalgary researcher David Cramb – who looks at using nanoparticles to deliver the drugs solely to the tumor in much smaller, more effective quantities shares the potential breakthroughs that can be made possible through nanomedicine both in the treatment and diagnosis of cancer. Watch the full webinar recording: http://www.ucalgary.ca/explore/nanomedicine-new-way-detect-and-treat-cancer
Nanoparticle, ultrafine unit with dimensions measured in nanometres (nm; 1 nm = 10−9 metre). Nanoparticles exist in the natural world and are also created as a result of human activities. Because of their microscopic size, they have unique material characteristics, and manufactured nanoparticles may find practical applications in a variety of areas, including medicine, engineering, catalysis, and environmental remediation.
Nano-Biomaterials and Their Biocompatibility in Restorative Dentistry: A Reviewinventionjournals
Human healthcare is facing a major uprising in the wake of ongoing technological expansions in the field of nanotechnology. Incorporation of nanotechnology into dentistry will make possible the maintenance of near perfect oral environment by using nanomaterials, including tissue engineering, and ultimately, dental nanorobots. New potential treatment prospects in dentistry may include: dentition renaturalization and permanent hypersensitivity cure, local anaesthesia, complete orthodontic realignments during a single office visit, covalently bonded diamondised enamel, and oral health maintenance using mechanical dentifrobots, to destroy bacteria in the mouth that cause dental caries or even repair spots on the teeth where decay has set in, by use of computer to direct these tiny workers in their tasks. Nanodentistry still faces many significant challenges in realizing its tremendous potential. There are larger social issues of public acceptance, regulations, ethics and human safety that must be taken into consideration before molecular nano-technology can enter the modern medical armamentarium. However, there is equally powerful motivation to surmount these various challenges such as the possibility of providing high quality dental care to 80% of the population that at present receives no noteworthy dental care. Time, financial and scientific resources, specific advances and human needs will conclude which of the applications to be realized first!
El programa INPhINIT está dirigido a los candidatos de doctorado más motivados y se centra en los campos de investigación en los que España destaca: las ciencias de la salud y de la vida, la tecnología, la física, la ingeniería y las matemáticas https://obrasociallacaixa.org/es/educacion-becas/becas-de-posgrado/inphinit/programme-description
Clinical applications of bionanotechnologyHari kesavan
Bionanotechnology is a science that sits at the convergence of nanotechnology and biology. Nanobiology and nanobiotechnology are other names that are used interchangeably with bionanotechnology.
This presentation is related to cancer treatment and involvement of the nanotechnology in cancer research. This has different nanotechnology-related delivery information.
Pegs Europe 2015 Protein & Antibody Engineering SummitNicole Proulx
PEGS Europe is the largest European event covering all aspects of protein and antibody engineering. With three consecutive years of 35% growth in attendance, and another year of expanded program coverage, this year’s event will feature:
700 attendees
175 technical presentations
125 scientific posters
Dedicated networking opportunities
Exclusive exhibit & poster viewing hours
Interactive roundtable, breakout & panel discussions
Sonogenetic Locale Specific Activation of Universal Vectors for Xenobiotics -...Nejc Draganjec
The final goal of the project is to develop “BioBrick” for liposome produced by means of synthetic biology, that
has a construct for disintegration embedded in its membrane. Xenobiotic packaged in a liposome is not part
of pharmacodynamics since it is biologically unavailable. Which makes liposomes interesting candidates for
universal drug delivery vectors. In our case, liposome disintegration is initiated by non-invasive sonic signal
and carried out by a construct of a sensor and an active part embedded in a membrane. Sensor part of a
construct is mechanoreceptor/mechanotransducer which activates protein representing the active part of a
construct. After activation, active part carries out the dissolution of a compartmentalization function by means
of total disintegration of vector or only membrane perforation. After an opening of a vector, previously packed
xenobiotic becomes locally available with a high concentration in locale and thus high effect and low systemic
concentration and thus smaller chance of side effect. This approach is very specific for both, time and space
factors and at the same time has a very broad area of potential biomedical applications. Vector would be, in
a hypothetical scenario of practical use in oncology, first packed with chemotherapeutics/biological drugs,
administered intravenously and then medical staff would have an option of drug activation in specific locations.
Activation is very precise and at the same time offers an option of easy switching among many different
targets, for example between dominant tumor to many potential metastasis. Since location of activation is
not tied to biomarker, but rather takes advantage of other rapidly developing medical technologies, vector
remains universally and directly applicable for any patient and for a broad spectrum of pathologies in fields of
oncology (chemotherapeutics/biological drugs and other payloads, like local immune response enhancers),
autoimmune diseases (local immune suppressors, diabetes), parasitology (malaria drugs and plasmodium
sporozoite), local pathologies (ulcer, trauma healing) . . .
Regular cancer treatment focuses on killing the cancer cells through large doses of medicine, but it also kills other cells in the body and causes significant side effects and potential long-term effects. UCalgary researcher David Cramb – who looks at using nanoparticles to deliver the drugs solely to the tumor in much smaller, more effective quantities shares the potential breakthroughs that can be made possible through nanomedicine both in the treatment and diagnosis of cancer. Watch the full webinar recording: http://www.ucalgary.ca/explore/nanomedicine-new-way-detect-and-treat-cancer
Nanoparticle, ultrafine unit with dimensions measured in nanometres (nm; 1 nm = 10−9 metre). Nanoparticles exist in the natural world and are also created as a result of human activities. Because of their microscopic size, they have unique material characteristics, and manufactured nanoparticles may find practical applications in a variety of areas, including medicine, engineering, catalysis, and environmental remediation.
Nano-Biomaterials and Their Biocompatibility in Restorative Dentistry: A Reviewinventionjournals
Human healthcare is facing a major uprising in the wake of ongoing technological expansions in the field of nanotechnology. Incorporation of nanotechnology into dentistry will make possible the maintenance of near perfect oral environment by using nanomaterials, including tissue engineering, and ultimately, dental nanorobots. New potential treatment prospects in dentistry may include: dentition renaturalization and permanent hypersensitivity cure, local anaesthesia, complete orthodontic realignments during a single office visit, covalently bonded diamondised enamel, and oral health maintenance using mechanical dentifrobots, to destroy bacteria in the mouth that cause dental caries or even repair spots on the teeth where decay has set in, by use of computer to direct these tiny workers in their tasks. Nanodentistry still faces many significant challenges in realizing its tremendous potential. There are larger social issues of public acceptance, regulations, ethics and human safety that must be taken into consideration before molecular nano-technology can enter the modern medical armamentarium. However, there is equally powerful motivation to surmount these various challenges such as the possibility of providing high quality dental care to 80% of the population that at present receives no noteworthy dental care. Time, financial and scientific resources, specific advances and human needs will conclude which of the applications to be realized first!
El programa INPhINIT está dirigido a los candidatos de doctorado más motivados y se centra en los campos de investigación en los que España destaca: las ciencias de la salud y de la vida, la tecnología, la física, la ingeniería y las matemáticas https://obrasociallacaixa.org/es/educacion-becas/becas-de-posgrado/inphinit/programme-description
Clinical applications of bionanotechnologyHari kesavan
Bionanotechnology is a science that sits at the convergence of nanotechnology and biology. Nanobiology and nanobiotechnology are other names that are used interchangeably with bionanotechnology.
This presentation is related to cancer treatment and involvement of the nanotechnology in cancer research. This has different nanotechnology-related delivery information.
Pegs Europe 2015 Protein & Antibody Engineering SummitNicole Proulx
PEGS Europe is the largest European event covering all aspects of protein and antibody engineering. With three consecutive years of 35% growth in attendance, and another year of expanded program coverage, this year’s event will feature:
700 attendees
175 technical presentations
125 scientific posters
Dedicated networking opportunities
Exclusive exhibit & poster viewing hours
Interactive roundtable, breakout & panel discussions
Tumour models London 1-3 December 2015 AgendaDiane McKenna
Tumour Models London 2015, now in its 4th year,is the leading meeting dedicated to improve preclinical predictability and translational success of oncology discoveries. Tackling clinical failures rates, preclinical strategies and translational challenges, this Summit will enable you to translate your discoveries from model to human studies with superior predictability to future proof clinical success. [Read More…]
Genomics is the study of an organism's entire genome, which is the complete set of genetic material present in its DNA. This includes all the genes, non-coding regions, and regulatory sequences. Genomics involves sequencing and analyzing the DNA to identify genes, variations (such as single nucleotide polymorphisms or SNPs), and other structural features of the genome.
Haapalinna the new modalities ecosystem project what is there for meAntti Haapalinna
The aim of this New Modalities Ecosystem is enable improved understanding of disease pathology related to the symptoms and disease progression and better treatments by applying large molecular drugs and diagnostic tools as well as digital wearable patient tools for disease symptom recording, to have real world evidence for treatment efficacy
2019 02-21 Oxford Global 14th Biomarker Congress, Manchester, Alain van GoolAlain van Gool
Outline of innovations in clinical X-omics approaches towards personalized diagnostics in our clinical laboratory, presented for an audience of experienced diagnostic and pharmaceutical biomarker scientists.
TCGC The Clinical Genome Conference 2015Nicole Proulx
Bio-IT World and Cambridge Healthtech Institute are again proud to host the Fourth Annual TCGC: The Clinical Genome Conference, inviting stakeholders impacting clinical genomics to share new findings and solutions for advancing the applications of clinical genome medicine.
Overcoming the challenges of molecular diagnostics in government health insti...Yakubu Sunday Bot
overcoming the challenges of molecular diagnostics in government owned health institution in nigeria.Several challenges abound in the Nigerian health sector ranging from financial,political and lack of commitment.Its obvious and no wonder the state of health care deliveryy, vis a vis its quality of care to its citizenry.
Similar to 2nd Epigenetics Discovery Congress - Latest agenda (20)
Biomaterials & Tissue engineering - London - AgendaTony Couch
Designed for experts in academia and industry working in this exciting field, this conference will examine cutting-edge
research in several key areas across four dedicated tracks. Talks will look to cover the development of scaffold
technology for both soft and hard tissues, and the novel biomaterials used in their construction, new platforms for
Biofabrication, tissue culture techniques, advances in hydrogels in regenerative medicine, and recent developments in
stem cell research. There will also be a track dedicated to the exciting developing field of organ fabrication, reviewing
recent advances and challenges to be overcome.
Precision Medicine & Biomarkers Leaders Summit - Boston USA - 7th & 8th MayTony Couch
This expanding series attracts the leading authorities worldwide working in companion diagnostics, biomarkers, immuno-oncology, liquid biopsies, AI and other facets of precision medicine. It has been praised for its stimulating, interactive and engaging environment where it brings together a multi-disciplined community of researchers, leaders and innovators whose aim is to develop groundbreaking and impactful treatments for patients.
Precision Medicine & Biomarkers Leaders Summit - Boston USA - 7th & 8th MayTony Couch
Tracks focus on R&D strategies, Biomarker development, Immuno-oncology, CDx development, AI and Big data analysis and approaches – Attending this Summit will provide you with the opportunity to mix and interact with experts working in all facets of Precision Medicine through the individual, panel and roundtable discussions on offer.
Precision Medicine & Biomarkers Leaders Summit - Boston USA - 7th & 8th MayTony Couch
Global Engage is pleased to announce the 2018 Precision Medicine & Biomarkers Leaders Summit USA taking place on May 7-8th in Boston, MA. The event is part of our highly successful Drug Discovery Series which includes conferences on Biologics, Medicinal Chemistry, NASH, Pharmaceutical R&D IT and the Human Microbiome amongst others. It is also the sister meeting of the European Precision Medicine Summit which has run successfully since 2013.
The conference will provide an interactive networking forum to both further develop and answer your queries through a vibrant exhibition room full of technology providers showcasing their technologies and other solutions, poster presentation sessions, expert led case study presentations, a high-level panel discussion, a round table discussion session, and interactive Q&A sessions from a 40-strong speaker faculty examining topics on 4 separate tracks outlined below.
Designed to attract experts working in all areas of medicinal chemistry and molecular pharmacology the summit has five tracks focusing on key issues such as optimising hit to lead quality and timescale, protein degradation, DNA Encoded libraries, GPCR’s, small molecule Immuno-oncology research, FBDD, SBDD, CADD as well as best strategies for partnerships, collaborations, outsourcing and integration of research. The Summit will provide a forum to network, learn and engage with senior representatives of leading pharmaceutical and biotech companies worldwide. It is a gathering not to be missed!
Designed to attract experts working in all areas of medicinal chemistry and molecular pharmacology the summit has five tracks focusing on key issues such as optimising hit to lead quality and timescale, protein degradation, DNA Encoded libraries, GPCR’s, small molecule Immuno-oncology research, FBDD, SBDD, CADD as well as best strategies for partnerships, collaborations, outsourcing and integration of research. The Summit will provide a forum to network, learn and engage with senior representatives of leading pharmaceutical and biotech companies worldwide. It is a gathering not to be missed!
After the success of the previous edition - Bioprocessing of Advanced Cellular Therapies Congress 2016, MarketsandMarkets is pleased to announce the 2nd Annual Bioprocessing of Advanced Cellular Therapies Congress in London, UK.
Research Organizations and Pharma companies have been investing big time into the promise of cellular therapies and all signs point to the need to accelerate the process of moving from lab to patient using advanced manufacturing processes and solutions to commercialization.
With this objective, making the shift from manual processes to automation, bridging the gap between research lab and market place, and using novel and advanced technologies will be the key aspects for manufacturers to answer the challenge of scale-out.
The 2nd Annual Bioprocessing of Advanced Cellular Therapies Congress taking place on the 8th and 9th June, 2017 in London, UK focuses on this holistic approach by discussing the next generation bioprocessing, strategies, technologies and solutions to work together for this constantly evolving field.
2nd Annual Infection Control, Sterilization and Decontamination in Healthcare...Tony Couch
After the success of inaugural congress held on 25th-26th February 2016, MnM Conferences is organizing 2nd Annual Infection Control, Sterilization and Decontamination in Healthcare Congress, scheduled for 21st & 22nd March 2017 in London, UK aiming at providing platform to experts from hospitals, academia, and government institutions discussing the innovations, challenges, and future aspects of infection control, decontamination, and sterilization.
Bioprocessing of Advanced Cellular Therapies CongressTony Couch
Last opportunity to get onto the programme.
Key sessions:
• Upstream process development for gene therapies
• Upstream process development for cell based therapies
• Downstream processing considerations
• Analytics - tackling measurement assurance for advanced cellular therapeutics
• Insights into Business Development and Reimbursement
• Regulatory perspectives
Bioprocessing of Advanced Cellular Therapies Congress
2nd Epigenetics Discovery Congress - Latest agenda
1. MnM CONFERENCES
FOR MORE INFORMATION PLEASE CONTACT
Tony at tony.couch@mnmconferences.com
MnM CONFERENCES
11
Review the importance of the strongly growing epigenetic market
Discuss the latest epigenetic breakthroughs in your field of epigenetic studies
Explore new avenues to network and showcase your epigenetic research work and discoveries
Discuss the use of Biomarkers as a tool for achieving optimal detection
Network with your academic and industry colleagues to brainstorm on latest epigenetic application
Review the latest epigenetic tools and technologies available in the market to aid your research
Why Attend?
2nd Annual
Epigenetics Discovery
Congress
Novel Inhibitors & Emerging Targets for Drug Discovery
8th
- 9th
September 2016, London, UK
MnM CONFERENCES
Epigenetics has flourished to become one of the most revolutionary areas of science over the past decade. Also, advances in the understanding
of epigenetic processes, have led to a burst in interest in this area as a potential source of new targets for the discovery of medicines.
While the promise of epigenetics is significant, it also presents some interesting challenges like pathways and mechanisms underlying epigenetics,
using right screening platforms, bottlenecks in translational and clinical phase, collating epigenetics data with proper analysis and finding the
right biomarkers.
At the 2nd
Annual Epigenetics Discovery Congress, which will be held on 8-9 September 2016 in London, UK aims to provide a
platform for researchers, academics and industry professionals working in epigenetic research to avail an opportunity & explore the potential of
epigenetics to contribute towards novel and existing therapeutics, current progress and trends in the inclusion of epigenetics in drug discovery
and development.
Along with the advancements in technologies and solutions, the conference will also focus on highlighting some of the emerging trends in terms of
drug discovery with respect to evolving targets, inhibitors, biomarkers and clinical success of epigenetics across various diseases.
2. MnM CONFERENCES
FOR MORE INFORMATION PLEASE CONTACT
Tony at tony.couch@mnmconferences.com
MnM CONFERENCES
2
Gold Sponsors:
Silver Sponsors:
Sponsor/Exhibitors:
Supporting Association:
THE EPIGENETICS SOCIETY
Media Partners:
3. MnM CONFERENCES
FOR MORE INFORMATION PLEASE CONTACT
Tony at tony.couch@mnmconferences.com
MnM CONFERENCES
3
Speakers:
Advisory Panel:
Dr. Tamara Maes
Chief Scientific Officer,
Oryzon, Spain
Dr. Paola B. Arimondo
Research Director,
CNRS EtaC, France
Dr. Hajji Nabil
Lecturer in epigenetics and
translational oncology, Imperial
College London, UK
Prof. A. Ganesan
Professor of Chemical Biology
University of East Anglia,
Norwich, UK
Dr. Brian Lohse
Associate Professor, EpiDiscoverY,
Faculty of Health and Medical
Sciences, Department of Drug Design
and Pharmacology, University of
Copenhagen, Denmark
Jenny Southgate
Director, Jack Birch Unit,
Department of Biology,
University of York, UK
Prof. Dr. Gianluca Sbardella
Associate Professor of
Medicinal Chemistry, Head of
EpigeneticMedChemLab
Università di Salerno, Italy
Prof. Guro Elisabeth Lind
Group leader Epigenetics, Department
of Molecular Oncology, Institute for
cancer research, Oslo University
Hospital, Norway
Dr. Manfred Koegl
Director Oncology Research
Boehringer Ingelheim, Vienna,
Austria
Dr. Tobias A. Knoch
Group Leader Biophysical Genomics,
Cell Biology & Genetics
Erasmus MC, Rotterdam,
The Netherlands
Dr. Gian Gaetano Tartaglia
Group Leader, Gene Function &
Evolution, Centre for Genomic
Regulation (CRG), Barcelona,
Spain
Prof. Irene Maeve Rea
Emeritus Professor, School of
Medicine, Dentistry and Biomedical
Science,Ulster University, Ireland
Prof. Dr. F.J. (Frank) Dekker
Associate professor, Medicinal
Chemistry, University of
Groningen, Netherlands
Dr. Stephen J Shuttleworth
Chief Scientific Officer
Karus Therapeutics Ltd, England
Dr. Richard Chesworth
Senior Vice President Molecular
Discovery
Epizyme, USA
Prof. Richard Meehan
Programme Leader, Chromosomes
and Gene Expression MRC Human
Genetics Unit MRC IGMM,
University of Edinburgh, UK
Prof. Rosalind M John
Division Leader for Pathophysiology
and Repair
Cardiff School of Biosciences, UK
Prof. Dr. Reinhard Stöger
Associate Professor in Epigenetics
University of Nottingham,
England
Dr. Moshe Szyf
Glaxo Smith Kline and James McGill
Professor, Department of Pharmacology
and Therapeutics, McGill University
Medical School, Canada
Prof. Dr. Manon van Engeland
Dept. of Pathology, GROW-School for
Oncology and Developmental Biology,
Maastricht University Medical
Center, Netherlands
Dr. Paola B. Arimondo
Research Director
CNRS EtaC, France
Dr. Tamara Maes
Chief Scientific Officer
Oryzon, Spain
Dr. Daniel Vitt
CSO
4SC AG, Germany
4. MnM CONFERENCES
FOR MORE INFORMATION PLEASE CONTACT
Tony at tony.couch@mnmconferences.com
MnM CONFERENCES
4
Conference Day One, Thursday, 8th
September 2016
08:00 Registration and Refreshments
08:50 MnM Conferences’ Welcome Address
08:55 Opening remarks by the Chair
Developmental Biology and Environment
09:00 Keynote address: Epigenetic regulation of the tumour micro environment (TME) - immuno oncology meets
epigenetics
• 4SC-202 is a new clinical stage epigenetic regulator of the TME
• Enhanced T-cell infiltration in tumours may offer a unique clinical boost of responses to checkpoint inhibitors
• Further approaches of epigenetic immune regulation - beyond HDAC inhibitors
Dr. Daniel Vitt, Vorstand, CSO, 4SC AG, Germany
09:25 Epigenetic profiling and environmental challenge
• 5mC/5hmC profiling tracks environmental exposure in model systems
• Allows identification of potential epigenetic predictors of end point pathologies
• Studying the effects of environmental triggers on the epigenome will enable identification of novel biomarkers
Prof. Richard Meehan, Programme Leader, Chromosomes and Gene Expression, MRC Human Genetics Unit MRC IGMM,
University of Edinburgh, UK
09:50 Stability and flux of DNA methylation patterns
• Genomic programs regulating energy balance evolved to be buffered or ‘canalised’ against genetic variation
• Large genetic regulatory networks can acquire novel epigenetic states in response to environmental challenges
• A new metric to quantify and compare epigenetic flexibility and stability across loci, cell types, and developmental stages
Prof. Dr. Reinhard Stöger, Associate Professor in Epigenetics, University of Nottingham, England
10:15 Presentation by NuGEN
10:45 Morning Refreshments | Networking | Poster presentation | One to One meetings
11:30 Environmental programming of maternal care and offspring behaviour by an epigenetic mechanism
• Prenatal environment and the developing placental epigenome
• Placental function and fetal growth
• Dual programming of maternal care and offspring behaviour
Prof. Rosalind M John, Division Leader for Pathophysiology and Repair, Cardiff School of Biosciences, UK
Translational Epigenetics
11:55 Overcoming bottlenecks in the translational phase
This session will focus on overcoming bottlenecks in the translational phase
Speaker invited: Prof. Dr. Steven Johnsen, University Medical Center Göttingen
12:20 Epigenetic regulation of epithelial homeostasis: an emerging story of health and disease
• Urothelium is a transitional epithelium that functions as a self-repairing, urinary barrier within the bladder and associated urinary tract.
• I will present experimental evidence that at the cellular level, the homeostasis of human urothelium is regulated epigenetically
• I will further consider how local and environmental factors effecting epigenetic deregulation can create an imbalance in tissue
homeostasis, with chronic ulceration versus cancer at the extremes of chronic bladder disease
Prof. Jenny Southgate, Director, Jack Birch Unit, Department of Biology, University of York, England
12:45 Presentation by Cell Signalling
13:15 Lunch | Networking | Poster presentation | One to One Meetings
14:15 Presentation by Roche/Kapa Biosystems Ltd.
5. MnM CONFERENCES
FOR MORE INFORMATION PLEASE CONTACT
Tony at tony.couch@mnmconferences.com
MnM CONFERENCES
5
Clinical Epigenetics and Biomarkers
14:40 DNA methylation biomarkers for early and non-invasive detection and monitoring of bladder cancer
• Using methylome sequencing (RRBS) to identify high performing DNA methylation biomarkers specific for bladder cancer
• Leveraging biomarkers to reduce the economic costs of bladder cancer
Prof. Guro Elisabeth Lind, Group leader Epigenetics, Department of Molecular Oncology, Institute for cancer research,
Oslo University hospital, Norway
15:05 Genetics or Lifestyle: Is Epigenetics the Missing link in the Longevity Phenotype?
• Human longevity is a complex trait and increasingly we recognise that both genes and lifestyle interact in the longevity
phenotype.
• Family clusters of nonagenarian and centenarian siblings, who show both exceptional age-span and health-span are likely to
have inherited facilitatory gene groups but also have nine decades of life experiences and behaviours which have interacted
with their genetic profiles.
• Although much remains to be discovered, this lecture will discuss some of the epigenetic and environmental factors which
appear important in good quality longevity and link known epigenetic mechanisms to themes identified by nonagenarians
themselves related to their longevity.
Prof. Irene Maeve Rea, Emeritus Professor School of Medicine, Dentistry and Biomedical Science, Ulster University, Ireland
15:30 Afternoon Refreshments | Poster Presentation | Networking | One to One Meetings
16:15 Solution Provider Presentation; contact steve.h@mnmconferences.com
16:45 DNA methylation markers for management of cancer: pitfalls and perspectives
• Discovery of DNA methylation markers
• Implementation of methylation markers into clinical practice
• Pitfalls and perspectives
Prof. Dr. Manon van Engeland, Dept. of Pathology, GROW-School for Oncology and Developmental Biology, Maastricht
University Medical Center, Netherlands
17:10 Decoding the 3D Multi-Loop Aggregate/Rosette Chromatin Architecture, Dynamics, and Functional Epigenetics of
Genomes
• Novel combination of chromosome interaction capture (T2C) and fluorescence correlation spectroscopy (FCS)
• Final architecture and dynamics of genome organization
• The tight entanglement of sequence, structure, and functional epigenetics
Dr. Tobias A. Knoch, Group Leader Biophysical Genomics, Cell Biology Genetics, Erasmus MC, Rotterdam, The
Netherlands
17:35 Closing Remarks by the Chair
17:45 Networking and Drinks Reception
6. MnM CONFERENCES
FOR MORE INFORMATION PLEASE CONTACT
Tony at tony.couch@mnmconferences.com
MnM CONFERENCES
6
Conference Day Two, Friday, 9th
September 2016
08:15 Registration and Refreshments
08:50 MnM Conferences’ Welcome Address
08:55 Opening remarks by the Chair
09:00 Keynote: Drug Discovery and HMTs
• Overview of Histone Methyl transferases
• Drug discovery of HMTs
• Clinical Data of HMTs so far
Dr. Richard Chesworth, Senior Vice President Research, Epizyme, USA
Epigenetics Inhibitors and Emerging Targets
09:25 KATching lysine acetylations in inflammation
• Role of lysine acetylation in inflammation
• Development of histone acetyltransferase inhibitors
• Selective HDAC inhibitors in inflammation
Prof. Dr. Frank Dekker, Associate professor, Medicinal Chemistry, University of Groningen, Netherlands
09:50 Targeting DNA methylation in cancer cells with non-nucleoside inhibitors
• We have designed novel non-nucleoside inhibitors of DNA methyltransferases able to demethylate and reactive tumor
suppressor genes.
• We applied three chemical strategies: High-Throughput Screening of chemical libraries, rational drug design based on
molecular modeling and the pharmacomodulation of known inhibitors.
• The cellular consequences of this DNA demethylation are studied in comparison to nucleoside inhibitor decitabine.
Dr. Paola B. Arimondo, CNRS, ETaC, France
10:15 Panel discussion
Fostering the culture of collaborations between industry and academic researchers to deliver innovation, translation and impact of
epigenetics on a global scale
• Nurturing translational research
• Initiating drug discovery projects in collaboration with industry
• Improving clinical development
-Dr. Stephen Shuttleworth, CSO, Karus Therapeutics, UK
-Prof. A. Ganesan, Professor of Chemical Biology, University of East Anglia, Norwich, UK
-Dr. Moshe Szyf, Glaxo Smith Kline and James McGill Professor, Department of Pharmacology and Therapeutics,
McGill University Medical School, Canada
-Prof. Jenny Southgate, Director, Jack Birch Unit, Department of Biology, University of York, England
10:45 Morning Refreshments – Networking – Poster presentation and One to One meetings
11:30 Solution Provider Presentation; Please contact Steve Hambrook at steve.h@mnmconferences.com
12:00 Strategies to identify new inhibitor scaffolds for Histone Demethylases and Methylases
• Strategies to discover new scaffolds: small molecules and peptides
• DNA encoded peptide libraries
• Fluorescence Assay development and testing on epigenetic targets
Dr. Brian Lohse, Associate Professor, EpiDiscoverY, Faculty of Health and Medical Sciences, Department of Drug Design and
Pharmacology, University of Copenhagen, Denmark
12:25 Is two better than one? Multitarget epigenetic inhibitors
• Dual HDAC plus kinase inhibitors
• Dual HDAC inhibitor plus receptor ligand
• Dual epigenetic targeting
Prof. A. Ganesan, Professor of Chemical Biology, University of East Anglia, Norwich, UK
7. MnM CONFERENCES
FOR MORE INFORMATION PLEASE CONTACT
Tony at tony.couch@mnmconferences.com
MnM CONFERENCES
7
MnM CONFERENCESMnM CONFERENCES
12:50 Probing genome readers: the generation of an in vivo active bromodomain inhibitor for BRD9
• The BAF complex is a potential target in cancer therapy
• Structure based drug design of a selective inhibitor of BRD9
• On-target chemical inhibition of Brd9 limits the proliferation of acute myeloid leukemia cells
Dr. Manfred Koegl, Director Oncology Research, Boehringer Ingelheim, Vienna, Austria
13:15 Lunch – Networking – Poster presentation and One to One Meetings
14:15 Presentation by Diagenode
Cancer and Neurodevelopment
14:45 Targeting DNA methylation in neuropsychiatric disease; instructions from cancer epigenetics
• DNA methylation mediating the impact of early exposures on behavioral phenotypes
• Strategies of epigenetic therapeutics in cancer guiding approaches to neuropsychiatry
• Epigenetic strategies towards treatment of behavioral disorders: addiction as a model
Dr. Moshe Szyf, Glaxo Smith Kline and James McGill Professor, Department of harmacology and Therapeutics,
McGill University Medical School, Canada
15:10 Development of LSD1 inhibitors for the treatment of oncological and neurodegenerative disease
• Development of ORY-1001 and ORY-2001
• Identification of the drugs’ modes of action
• Status of ongoing clinical research
Dr. Tamara Maes, Chief Scientific Officer, Oryzon, Spain
15:35 Design and Development of a Novel HDAC6-Selective Inhibitor, KA2507, for Hematological Cancer Treatment
and Solid Tumor Immunotherapy
• Functional mechanisms of lncRNAs
• Application of high-throughput technologies, to clarify how lncRNAs regulate diverse biological processes in physiological and
pathophysiological states
Dr. Stephen Shuttleworth, CSO, Karus Therapeutics, UK
16:00 Afternoon Refreshments | Poster Presentation | Networking
16:40 A “library-on-library” screening approach to identify small-molecule ligands of methyl-lysine reader proteins
• Methyllysine readers
• Chemical probes
• Protein arrays
Prof. Dr. Gianluca Sbardella, Associate Professor of Medicinal Chemistry, Head of EpigeneticMedChemLab, Università di
Salerno, Italy
Bioinformatics Development in Epigenetics
17:05 A computational approach for identification of protein-RNA interactions uncovers direct binders of Xist lncRNA
• Global Score algorithm to calculate interactions of proteins and lncRNAs at nucleotide and amino acid resolution
• Investigating protein binding to the Xist lncRNA, which orchestrates X Chromosome inactivation
• Validating calculations by means of enhanced individual nucleotide CLIP method (eCLIP)
• Testing method against a number of nucleotide-binding proteins
Dr. Gian Gaetano Tartaglia, Group Leader, gene Function Evolution, Centre for Genomic Regulation (CRG), Barcelona, Spain
17:30 Closing Remarks by the Chair
17:35 End of Conference